190 related articles for article (PubMed ID: 28704854)
21. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin.
Barnett AH; Charbonnel B; Donovan M; Fleming D; Chen R
Curr Med Res Opin; 2012 Apr; 28(4):513-23. PubMed ID: 22313154
[TBL] [Abstract][Full Text] [Related]
22. Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes.
da Silva GM; Nogueira KC; Fukui RT; Correia MR; Dos Santos RF; da Silva ME
Curr Pharm Des; 2016; 22(44):6716-6721. PubMed ID: 27928958
[TBL] [Abstract][Full Text] [Related]
23. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
24. Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study.
Oe Y; Nomoto H; Nakamura A; Kuwabara S; Takahashi Y; Yasui A; Izumihara R; Miya A; Kameda H; Cho KY; Atsumi T; Miyoshi H
J Diabetes Res; 2022; 2022():5603864. PubMed ID: 35097130
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of switching from premixed insulin to insulin glargine regimen in Type 2 diabetes mellitus patients with different islet functions.
Wang YB; Wang S; Bai R; Du JL; Xing Q; Ba Y; Yang Y; Zhang XY; Shi CH; Yao JJ
Mol Med Rep; 2014 Aug; 10(2):1096-102. PubMed ID: 24859808
[TBL] [Abstract][Full Text] [Related]
26. Glycemic Improvement with a Fixed-dose combination of DPP-4 inhibitor + metformin in patients with Type 2 diabetes (GIFT study).
Bajaj HS; Ye C; Jain E; Venn K; Stein E; Aronson R
Diabetes Obes Metab; 2018 Jan; 20(1):195-199. PubMed ID: 28640433
[TBL] [Abstract][Full Text] [Related]
27. Individualised incretin-based treatment for type 2 diabetes.
Nauck MA; Meier JJ
Lancet; 2010 Aug; 376(9739):393-4. PubMed ID: 20580425
[No Abstract] [Full Text] [Related]
28. Improved Erythrocyte Deformability Induced by Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetic Patients.
Son M; Lee YS; Hong AR; Yoon JH; Kim HK; Kang HC; Yang S
Cardiovasc Drugs Ther; 2022 Feb; 36(1):59-67. PubMed ID: 32886218
[TBL] [Abstract][Full Text] [Related]
29. Association between glucose-lowering treatment and cancer metastasis among patients with preexisting type 2 diabetes and incident malignancy.
Noh Y; Jeon SM; Shin S
Int J Cancer; 2019 Apr; 144(7):1530-1539. PubMed ID: 30229901
[TBL] [Abstract][Full Text] [Related]
30. Clinical study of treatment switching from premixed insulin to basal insulin combined with oral hypoglycemic drugs in patients with type 2 diabetes.
Zhang Y; Xie YJ; Meng DD; Zhang HH; Chen H; Liu E
Diabetol Metab Syndr; 2014 Mar; 6(1):37. PubMed ID: 24620742
[TBL] [Abstract][Full Text] [Related]
31. Safety And Efficacy Of Dpp-4 Inhibitors For The Management Of Hospitalized General Medicine And Surgery Patients with Type 2 Diabetes.
Lorenzo-González C; Atienza-Sánchez E; Reyes-Umpierrez D; Vellanki P; Davis GM; Pasquel FJ; Cardona S; Fayfman M; Peng L; Umpierrez GE
Endocr Pract; 2020 Jul; 26(7):722-728. PubMed ID: 33471640
[TBL] [Abstract][Full Text] [Related]
32. Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes.
Montvida O; Green JB; Atherton J; Paul SK
Diabet Med; 2019 Apr; 36(4):491-498. PubMed ID: 30306620
[TBL] [Abstract][Full Text] [Related]
33. Premixed vs basal-bolus insulin regimen in Type 2 diabetes: comparison of clinical outcomes from randomized controlled trials and real-world data.
Anyanwagu U; Mamza J; Gordon J; Donnelly R; Idris I
Diabet Med; 2017 Dec; 34(12):1728-1736. PubMed ID: 28945928
[TBL] [Abstract][Full Text] [Related]
34. Study of Once Daily Levemir (SOLVE™): insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice.
Khunti K; Damci T; Meneghini L; Pan CY; Yale JF;
Diabetes Obes Metab; 2012 Jul; 14(7):654-61. PubMed ID: 22443213
[TBL] [Abstract][Full Text] [Related]
35. Vildagliptin vs. insulin treatment alone in diabetic acute coronary syndrome patients.
Dobrecky-Mery I; Sommer A
Coron Artery Dis; 2021 Jan; 32(1):4-9. PubMed ID: 32310854
[TBL] [Abstract][Full Text] [Related]
36. Transitioning from insulin to dipeptidyl-peptidase 4 (DPP-4) inhibitors for type 2 diabetes.
Hamrick I; Goblirsch MJ; Tuan WJ; Beckham F
Geriatr Nurs; 2022; 46():86-89. PubMed ID: 35613488
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of Dipeptidyl Peptidase-IV Inhibitor Use in Hospitalized Patients With Diabetes.
Petite SE; Hill MC
Ann Pharmacother; 2021 Nov; 55(11):1326-1332. PubMed ID: 33615832
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of basal insulin therapy in type 2 diabetes mellitus patients with or without metformin observed in a national cohort in China.
Zhang P; Chen M; Zhang H; Luo Y; Zhu D; Li X; Ji J; Wang D; Duolikun N; Ji L
BMC Endocr Disord; 2022 Jan; 22(1):26. PubMed ID: 35045841
[TBL] [Abstract][Full Text] [Related]
39. Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients.
Esposito K; Chiodini P; Bellastella G; Maiorino MI; Giugliano D
Diabetes Obes Metab; 2012 Mar; 14(3):228-33. PubMed ID: 21958121
[TBL] [Abstract][Full Text] [Related]
40. Dose adjustment of metformin and dipeptidyl-peptidase IV inhibitors in diabetic patients with renal dysfunction.
Melzer-Cohen C; Karasik A; Leuschner PJ; Azuri J; Shalev V; Chodick G
Curr Med Res Opin; 2018 Oct; 34(10):1849-1854. PubMed ID: 29611727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
